T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

NCT02659943 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

NIH

Sponsor class

Conditions

Lymphoma, B-Cell
Lymphoma, Non-hodgkins

Interventions

BIOLOGICAL: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

National Cancer Institute (NCI)